Test |
Baseline |
Weekly for 4 Weeks |
Monthly for 3 Months |
Quarterly |
Yearly |
When Symptoms Arise |
Special Considerations |
---|---|---|---|---|---|---|---|
Pregnancy test |
X |
X |
In women of childbearing age. Category D. 0.1-0.7% absolute risk of Ebstein’s anomaly of tricuspid valve (normal population = 0.01%). | ||||
Complete blood count |
X |
X |
Most frequently benign leukocytosis >15 K white blood cell count (WBC)/mm3. Reverses with discontinuation. Exclude infection. | ||||
Blood chemistries (including renal tests) |
X |
X |
X |
Discontinue if fluctuating or unstable renal function and consult with medicine/nephrology. | |||
ECG |
X |
X |
X |
Indicated in patients >40 years and/or history of cardiac disease. Discontinue with sinus disease or conduction defects. May reveal transient T wave inversion/flattening that often normalizes with either continuation or discontinuation of lithium. | |||
Urinalysis |
X |
X |
Management of lithium-induced nephrogenic diabetes insipidus (often reversible if lithium discontinued). 1. Increase fluid intake. 2. Consider K 10-20 mEq/d. 3. Consider thiazide (caution), amiloride (non-thiazide & preferred) 5-10 mg p.o. BID. 4. Discontinue lithium. 5. Continue electrolyte monitoring. If lithium must be continued, decrease to lowest effective dose & QD if able. Monitor lithium level minimum q 2 months. Proteinuria indicative of glomerular & tubule damage. | ||||
Thyroid function tests |
X |
X |
Increased risk in women & rapid cyclers. Usually reversible hypothyroidism. Evaluate for signs/symptoms and refer to endocrinology. May continue if adequately treated & monitored. | ||||
Serum plasma concentrations |
X |
X |
X |
X |
X |
0.8-1.2 (lower in elderly). Toxicity possible at lower serum concentrations. Monitor for clinical symptoms of toxicity. | |
Weight/body mass index (BMI)/waist circumference |
X |
Possible mechanism due to polydipsia, carbohydrate & lipid metabolism, glucose tolerance. Diet, exercise & low-calorie liquids. | |||||
Adapted from Gelenberg AJ. Laboratory and other testing for patients taking psychotropic medications. Biological Therapies in Psychiatry. 2004;27(11):41-44. |
Test |
Baseline |
2 Weeks |
Monthly for 6 Months |
Quarterly |
Every 6 Months |
Yearly |
When Symptoms Arise |
Special Considerations |
---|---|---|---|---|---|---|---|---|
Pregnancy test |
X |
X |
In women of childbearing age. Neural tube defects 1%-2% first trimester. | |||||
Complete blood count with platelets and differential |
X |
X |
X |
X |
Clinically significant thrombocytopenia rare. | |||
Blood chemistries |
X |
X |
X |
X |
At high doses, mild to moderate hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH. Reversible when lower dose) | |||
Serum plasma concentrations |
X |
X |
X |
50-125 mcg/ml trough levels. | ||||
Prothrombin time |
X |
X |
X |
Monitor liver function. | ||||
Weight/BMI/waist circumference |
X |
X |
Common. Not dose dependent. | |||||
Amylase |
X |
Rare cases of pancreatitis. Most commonly first 6 months. | ||||||
Liver function |
X |
X |
Liver function tests optional. Discontinue if >2.5 times normal AST/ALT. Plasma NH3 often increased transiently and may not necessarily mandate interruption of treatment. | |||||
Serum androgen assays |
X |
Symptoms of polycystic ovarian syndrome include obesity, hirsutism, amenorrhea. | ||||||
Adapted from Gelenberg AJ. Laboratory and other testing for patients taking psychotropic medications. Biological Therapies in Psychiatry. 2004;27(11):41-44. |

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

